Portfolio Rapha Capital Management

Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T

By Kevin SlawinJanuary 6, 2019February 4th, 2021No Comments

Poseida Therapeutics, Inc.
Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T
January 6, 2019

Previous PostSightly and Horizon Media score over 99% in IAS YouTube brand safety measurement beta
Next PostBellicum Pharmaceuticals: Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO

© 2024 Ponce Therapeutics. Privacy Policy | Terms & Conditions